Stephen K. Brannan - Jul 11, 2022 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol: KRTX
Transactions as of: Jul 11, 2022
Transactions value $: -$1,861,350
Form type: 4
Date filed: 7/11/2022, 06:30 PM
Previous filing: Jun 9, 2022
Next filing: Aug 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$138K	+15K	+100%	$9.20^*	30K	Jul 11, 2022	Direct
transaction	KRTX	Common Stock	Sale	-$2M	-15K	-50%	$133.29	15K	Jul 11, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-15K	-30.01%	$0.00	35K	Jul 11, 2022	Common Stock	15K	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.28 to $133.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.